GHRP-6: The Peptide That Predicted a Hormone
The compound that started the entire growth hormone secretagogue field. It worked through a receptor nobody could identify, which led its discoverer to insist a natural hormone must exist to explain it. Fourteen years later, ghrelin was found.
What Is GHRP-6?
GHRP-6 is a hexapeptide — six amino acids — that prompts the pituitary to release growth hormone. It was the first compound of its kind, developed in 1984 by the American endocrinologist Cyril Bowers, and every growth hormone secretagogue that followed, Ipamorelin included, descends from this line of work.
The discovery was partly accidental. Bowers was working with modified enkephalin amides — compounds related to the body’s own opioid signalling — when he noticed something unexpected: certain modifications produced potent growth hormone release in pituitary cell cultures. That was not what the molecules were designed to do.
The Part That Makes It Remarkable
GHRP-6 clearly worked, and it clearly did not work through the known growth hormone pathway. GHRH — growth hormone-releasing hormone — was the recognised signal, and this compound was not using it. It was acting on some other receptor entirely, one nobody had identified.
Bowers drew the conclusion most people would not have dared to: if a synthetic compound is activating an unknown receptor, then the body must make its own molecule for that receptor. A receptor does not exist to be triggered by a laboratory peptide. Something natural must fit it.
He was right. In 1999, fifteen years after GHRP-6, researchers identified ghrelin — the body’s own hormone for that receptor, produced mainly in the stomach, and now familiar as a major hunger signal.
Why that is unusual, in plain language: normally science runs discovery first, drug second — you find the lock, then cut a key. Bowers cut a key that worked, found no lock anyone knew about, and reasoned backwards that the lock must be there. Then somebody went and found it. Working out that a hormone exists because something you made in a laboratory keeps behaving as though it does is a genuinely rare piece of reasoning.
The Side of It Nobody Expected
Because GHRP-6 acts on the ghrelin receptor, and ghrelin turned out to be a principal hunger hormone, GHRP-6 produces pronounced appetite stimulation. This was discovered before anyone knew why it happened.
That property is central to how GHRP-6 sits relative to newer compounds. It is why Ipamorelin was developed — a selective secretagogue that engages the growth hormone pathway with far less of the appetite and hormonal spillover. GHRP-6 also produces increases in cortisol and prolactin, which later compounds were specifically designed to avoid.
So the family reads as a progression: GHRP-6 established that the pathway existed and could be triggered, and everything after it has been an exercise in triggering the same pathway more cleanly.
Why the pulse pattern matters. The pituitary does not release growth hormone in a steady stream. It releases it in bursts, concentrated heavily during deep sleep, with quiet periods in between. That rhythm appears to be part of the signal rather than an inconvenience — tissues respond differently to a pulse than to a constant level, which is why research on this family measures release patterns over hours rather than simply totals. It is also why the literature pairs GHRPs with GHRH analogues: the two pathways shape different aspects of that pattern.
The enkephalin connection. There is a further oddity worth noting. GHRP-6 came out of work on modified enkephalin amides — molecules related to the body’s own opioid signalling, which have nothing obvious to do with growth hormone. That a compound derived from that starting point turned out to activate an entirely unrelated hormone system is a reminder of how much of this field was mapped by following unexpected results rather than by design. The ghrelin system, now understood as central to hunger and energy balance, was found because a growth hormone experiment produced a result nobody had predicted.
Where the Evidence Stands
GHRP-6 has a substantial preclinical literature spanning four decades, and its historical importance is not in question — the ghrelin system was mapped in large part through work on these compounds.
It holds no regulatory approval in any jurisdiction. Interest in it has since expanded beyond growth hormone into cytoprotection — research examining effects on cardiac and other tissue under stress — though this remains preclinical.
For anyone reading the GH literature, GHRP-6 is best understood as the reference ancestor: the compound the others were measured against and designed to improve upon.
Frequently Asked Questions
Compiled by the Southern Pacific Labs research team. Last updated July 2026.
Published References
- Bowers CY, Momany FA, Reynolds GA, et al. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology, 1984. PubMed
- Kojima M, Hosoda H, Date Y, et al. “Ghrelin is a growth-hormone-releasing acylated peptide from stomach.” Nature, 1999. PubMed
- Berlanga-Acosta J, Abreu-Cruz A, Herrera DGB, et al. “Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects.” Clinical Medicine Insights. Cardiology, 2017. PubMed
- Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European journal of endocrinology, 1998. PubMed
Related Research Guides
More in Growth Hormone & Endocrine
Two doors to the same room — how GHRH analogues and GHRPs differ.
Read guide →Selective GHRPThe selective successor developed to avoid GHRP-6’s appetite and hormonal spillover.
Read guide →GHRH AnalogueThe other pathway — a GHRH analogue rather than a ghrelin receptor agonist.
Read guide →